Compare · CRON vs DFTX
CRON vs DFTX
Side-by-side comparison of Cronos Group Inc. (CRON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $3.95B, about 3.9x CRON ($1.01B).
- DFTX has been more active in the news (21 items in the past 4 weeks vs 4 for CRON).
- CRON has more recent analyst coverage (11 ratings vs 5 for DFTX).
- Company
- Cronos Group Inc.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.01B
- $3.95B
- 1M return
- -1.28%
- -
- 1Y return
- +42.22%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 4
- 21
- Recent ratings
- 11
- 5
Cronos Group Inc.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Latest CRON
- Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders
- Cronos Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Cronos Announces Extension of Share Repurchase Program to the Toronto Stock Exchange
- Spinach® is the Number One Vape Brand in Canada
- Officer Doucet Terrence Gregory Joseph converted options into 10,597 shares and covered exercise/tax liability with 5,199 shares, increasing direct ownership by 5% to 110,588 units (SEC Form 4)
- Officer Wagner Adam converted options into 10,367 shares, increasing direct ownership by 11% to 103,987 units (SEC Form 4)
- Officer Buggy Shannon converted options into 20,622 shares and covered exercise/tax liability with 9,179 shares, increasing direct ownership by 7% to 178,322 units (SEC Form 4)
- Officer Kenost Jared Matthew converted options into 9,412 shares and covered exercise/tax liability with 3,701 shares, increasing direct ownership by 15% to 42,974 units (SEC Form 4)
- Officer Weigensberg Arye converted options into 3,118 shares, increasing direct ownership by 1% to 211,555 units (SEC Form 4)
- Officer Wagner Adam converted options into 20,470 shares, increasing direct ownership by 28% to 93,620 units (SEC Form 4)
Latest DFTX
- Needham reiterated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics, Inc. Announces Proposed Public Offering
- SEC Form 424B5 filed by Definium Therapeutics Inc.
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 24% to 513,317 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 50% to 1,127,454 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 23% to 333,579 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 42% to 212,500 units (SEC Form 4)
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 54% to 177,500 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder